In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...

Post-diagnostic hyperglycaemia in patients with bladder cancer is associated with poor cancer-specific and overall survival, a population-based cohort study shows.

BOOG 13-08 shows skipping sentinel lymph node biopsy in patients 50+ with early-stage, hormone receptor–positive, ...

At the San Antonio Breast Cancer Symposium, researchers presented findings on Clarity BCR, a multimodal multitask ...

A growing body of evidence suggests GLP-1 receptor agonists may improve survival as well as reduce chemotherapy-related toxicities in women with breast cancer.

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

Patients with stage I or II hormone receptor-negative breast cancer do not benefit from preoperative breast MRI, according to data from San Antonio Breast Cancer Symposium.Given the comparable 5-year ...

Sacituzumab govitecan failed to extend PFS in patients with hormone receptor-positive, HER2-negative breast cancer following endocrine therapy, according to data from San Antonio Breast Cancer ...

Pfizer’s Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive ...

ctDNA offers a minimally invasive alternative for detecting PIK3CA, AKT1, and PTEN alterations in hormone receptor-positive breast cancer when tissue is unavailable. The CAPItello-291 trial showed ...